Corporate Communications, CEL-SCI Corporation Company Profile

00:27 EST 16th December 2018 | BioPortfolio

CEL-SCI Corporation (AMEX: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The Company’s core capabilities include drug discovery, research, development and manufacturing of complex biological substances.Recurrence of cancer is the greatest fear for the cancer patient and the treating physician. Wouldn’t it be great if we had an agent that could be used to enhance the success rate of the first cancer therapy? We think that our drug Multikine® is such an agent.Multikine is a combination, or "cocktail", of natural human interleukin-2 (IL-2) and certain lymphokines and cytokines (regulators of the immune system). In human testing Multikine has been shown to induce both an anti-cancer immune response and to significantly increase the susceptibility of the tumor cells to radiation therapy.


8229 Boone Boulevard, Suite 802
United States of America

News Articles [565 Associated News Articles listed on BioPortfolio]

Orion Corporation: Managers' transactions - Nina Karvonen

ORION CORPORATION         MANAGERS' TRANSACTIONS 20 June 2018 at 12.00 EEST Orion Corporation: Managers' transactions - Nina Karvonen Orion Corporation has recei...

Orion Corporation: Managers' transactions - Anne Karvonen

ORION CORPORATION      MANAGERS' TRANSACTIONS 20 June 2018 at 11.45 EEST Orion Corporation: Managers' transactions - Anne Karvonen Orion Corporation has received the fo...

Orion Corporation's financial reporting and Annual General Meeting in 2019

ORION CORPORATION          STOCK EXCHANGE RELEASE           18 JULY 2018 at 11.00 EEST                       Orion Corporation's fina...

Adverum Biotechnologies Appoints Katherine Bock as Vice President, Investor Relations & Corporate Communications

MENLO PARK, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular dis...

Virbac: Availability of the quarterly financial information as of September 30, 2018

Virbac: Availability of the quarterly financial information as of September 30, 2018 Public release - November 14, 2018 The quarterly financial information as of September 30, 2018 is avai...

Publishing of Orion Corporation's Half-Year Financial Report for January-June 2018 on 18 July 2018

ORION CORPORATION                     PRESS RELEASE                   5 JULY 2018 at 11.30 EEST Publishing of Orion Corporation's H...

Invitation: Terveystalo Plc Q3 result - webcast and conference call on 14 November 2018

Terveystalo Plc will publish its Interim report for January-September 2018 on 14 November at 9:00 EEST. (Finnish time). The English live webcast and conference call will be held on 14 Novembe...

Invitation to Idorsia's half year financial results 2018 webcast and conference call

Idorsia Pharmaceuticals Ltd. / Invitation to Idorsia's half year financial results 2018 webcast and conference call . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is sole...

PubMed Articles [25 Associated PubMed Articles listed on BioPortfolio]

PrEP Communications Accelerator: a digital demand creation tool for sub-Saharan Africa.

Strategic communications are critical for successful market introduction of oral pre-exposure prophylaxis (PrEP). This paper focuses on the OPTIONS Consortium's approach to developing the PrEP Communi...

XXXII Reunion da Sociedade Galega de Neuroloxia. Communications.

Newborn Screening and Health Communications.

Erratum: Publisher Correction: genomes reveal adaptive evolution of functions related to coral-dinoflagellate symbiosis.

[This corrects the article DOI: 10.1038/s42003-018-0098-3.].

Erratum: Author Correction: The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures.

[This corrects the article DOI: 10.1038/s42003-018-0017-7.].

Clinical Trials [14 Associated Clinical Trials listed on BioPortfolio]

Multi-level Communications and Access Strategies to Improve the Food Environment

The overarching goal of B'More Healthy Retail Rewards (BHRR) is to develop, implement, and evaluate a pilot multi-level communications and pricing intervention to improve access to and con...

HERrespect Evaluation

This study evaluates whether a factory wide intervention, HERrespect, can reduce female garment workers' experiences of intimate partner violence, and experience and/or witnessing of viole...

Improving the Outpatient Referral Process With Electronic Communications

An electronic referral application will be developed and integrated into the existing outpatient information system. The primary goal of this software is to improve the quality and coordi...

The ACHIEVA Study of Enhanced Pharmacist Care on Antidepressant Use and Response

This a comparative study of enhanced pharmacist care and regular care of patients starting on antidepressants. When providing participants with enhanced care pharmacists will use the Healt...

Electronic Communications and Home Blood Pressure Monitoring

The control of blood pressure (BP) for patients with hypertension on medications has been elusive, despite the availability of evidence-based nationally recognized guidelines for treatment...

Companies [700 Associated Companies listed on BioPortfolio]


Corporate Action Network

Corporate Action Network was founded to address the imbalance of power between corporations and people. Using the new tools of the Action Network and a networked approach, Corpora...

NEC Corporation of America

NEC Corporation of America (NEC) is a leading technology integrator providing solutions that improve the way people work and communicate. NEC delivers integrated Solutions for Soc...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

XO Communications

XO Communications provides the technology that helps business and wholesale customers compete in a hyper-connected economy. In the U.S., XO owns and operates one of the largest IP...

More Information about "Corporate Communications, CEL-SCI Corporation" on BioPortfolio

We have published hundreds of Corporate Communications, CEL-SCI Corporation news stories on BioPortfolio along with dozens of Corporate Communications, CEL-SCI Corporation Clinical Trials and PubMed Articles about Corporate Communications, CEL-SCI Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Corporate Communications, CEL-SCI Corporation Companies in our database. You can also find out about relevant Corporate Communications, CEL-SCI Corporation Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Corporate Database Quicklinks

Searches Linking to this Company Record